Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Obtained By Apheresis Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector, Encoding A Chimeric Antigen Receptor (Car) Consisting Of An Anti-Cd19 Specific Scfv, A Cd8.Alpha. Stalk, Transmembrane Domain And Anchor, A 41Bb Endodomain And A Cd3 Zeta Endodomain, Under The Control Of A Human Pgk1 Promoter And A Modified Woodchuck Post Transcriptional Response Element. The Vector Genome Also Contains A 5' Terminal Cmv Enhancer/Promoter, A .Psi. Packaging Signal, A Rev Response Element (Rre) And A Central Polypurine Tract (Cppt)
B-Cell Acute Lymphoblastic Leukemia
Explore 136 assets in B-Cell Acute Lymphoblastic Leukemia →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Autolus Limited
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06173518CT.gov A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | — | Recruiting | — | — | — |
NCT04404660CT.gov A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | — | Active Not Recruiting | — | — | — |
NCT06799221CT.gov Expanded Access Program for OOS Obe-cel | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Obtained By Apheresis Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector, Encoding A Chimeric Antigen Receptor (Car) Consisting Of An Anti-Cd19 Specific Scfv, A Cd8.Alpha. Stalk, Transmembrane Domain And Anchor, A 41Bb Endodomain And A Cd3 Zeta Endodomain, Under The Control Of A Human Pgk1 Promoter And A Modified Woodchuck Post Transcriptional Response Element. The Vector Genome Also Contains A 5' Terminal Cmv Enhancer/Promoter, A .Psi. Packaging Signal, A Rev Response Element (Rre) And A Central Polypurine Tract (Cppt) (this asset) | Autolus Limited | P1/2 | CCC · 54 |
| Etoposide | University of Washington | P3 | BBB |
| Vincristine Sulfate | City of Hope Medical Center | P3 | BB |
| Crisantaspase | City of Hope Medical Center | P3 | BB |
| Nivestim | University of Washington | P3 | BB |
| Dasatinib | National Cancer Institute (NCI) | P3 | BB |
| Pegaspargase | National Cancer Institute (NCI) | P3 | BB |
| Mercaptopurine Anhydrous | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | SWOG Cancer Research Network | P3 | BB |
+42 more in the B-Cell Acute Lymphoblastic Leukemia cohort
Other indications for Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Obtained By Apheresis Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector, Encoding A Chimeric Antigen Receptor (Car) Consisting Of An Anti-Cd19 Specific Scfv, A Cd8.Alpha. Stalk, Transmembrane Domain And Anchor, A 41Bb Endodomain And A Cd3 Zeta Endodomain, Under The Control Of A Human Pgk1 Promoter And A Modified Woodchuck Post Transcriptional Response Element. The Vector Genome Also Contains A 5' Terminal Cmv Enhancer/Promoter, A .Psi. Packaging Signal, A Rev Response Element (Rre) And A Central Polypurine Tract (Cppt)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P1 | CC · 43 |
| Adult Acute Lymphoblastic Leukemia | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Obtained By Apheresis Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector, Encoding A Chimeric Antigen Receptor (Car) Consisting Of An Anti-Cd19 Specific Scfv, A Cd8.Alpha. Stalk, Transmembrane Domain And Anchor, A 41Bb Endodomain And A Cd3 Zeta Endodomain, Under The Control Of A Human Pgk1 Promoter And A Modified Woodchuck Post Transcriptional Response Element. The Vector Genome Also Contains A 5' Terminal Cmv Enhancer/Promoter, A .Psi. Packaging Signal, A Rev Response Element (Rre) And A Central Polypurine Tract (Cppt) in B-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-cd4-and-cd8-t-cells-enriched-from-peripheral-blood-mononuclear-cells-pbmcs-obtained-by-apheresis-transduced-ex-vivo-with-a-non-replicating-self-inactivating-sin-lentiviral-vector-encoding-a-chimeric-antigen-receptor-car-consisting-of-an-anti-cd19-specific-scfv-a-cd8alpha-stalk-transmembrane-domain-and-anchor-a-41bb-endodomain-and-a-cd3-zeta-endodomain-under-the-control-of-a-human-pgk1-promoter-and-a-modified-woodchuck-post-transcriptional-response-element-the-vector-genome-also-contains-a-5-terminal-cmv-enhancerpromoter-a-psi-packaging-signal-a-rev-response-element-rre-and-a-central-polypurine-tract-cppt-b-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →